Metastatic Breast Cancer 2025 UPDATE
Two Onc Docs
00:00
Second-Line and ADCs in Triple-Negative Disease
Hosts discuss HER2-low T-DXd use, sacituzumab govitecan and its toxicities, and emerging trial data like ASCENT Breast 04.
Play episode from 09:27
Transcript
